Upstream Bio's CEO will participate in November investor conferences discussing innovations in treating severe respiratory disorders.
Quiver AI Summary
Upstream Bio, Inc., a clinical-stage biotechnology company focused on developing treatments for inflammatory diseases, announced that its CEO, Dr. Rand Sutherland, will participate in several investor conferences in November 2025. These include the Truist Securities BioPharma Symposium on November 6, the Stifel Healthcare Conference on November 11, and the TD Cowen Immunology and Inflammation Summit on November 12, with live webcasts available on the company’s website. Upstream Bio is advancing its lead drug candidate, verekitug, a monoclonal antibody targeting the thymic stromal lymphopoietin receptor, through Phase 2 trials for conditions such as chronic rhinosinusitis with nasal polyps, severe asthma, and chronic obstructive pulmonary disease, aiming to address significant unmet medical needs.
Potential Positives
- Participation of CEO Rand Sutherland in notable investor conferences enhances the company's visibility and credibility within the biotech sector.
- Advanced clinical development of verekitug positions Upstream Bio at the forefront of treating inflammatory diseases with significant unmet patient needs.
- Verekitug's unique mechanism of action targeting TSLP offers a potential breakthrough in treating severe respiratory disorders, differentiating Upstream Bio from competitors.
- Live webcasts and replays provide transparency and accessibility for investors, fostering greater engagement with the company's developments.
Potential Negatives
- Participation in investor conferences may indicate a need for greater visibility and assurance of investor confidence amidst challenges typical for clinical-stage biotechnology companies.
- The mention of multiple clinical trials suggests operational complexity that could lead to increased risk and resource demands, potentially straining company resources.
- Focus on a single drug candidate, verekitug, may highlight reliance on its success, which poses a risk in case of setbacks in clinical trials or regulatory challenges.
FAQ
What events will Upstream Bio's CEO participate in November 2025?
Rand Sutherland, MD, will participate in the Truist Securities BioPharma Symposium, Stifel Healthcare Conference, and TD Cowen Immunology Summit.
How can I watch Upstream Bio's investor presentations?
Live webcasts of the Stifel and Cowen presentations will be available on Upstream Bio's website under the Events tab.
What is the focus of Upstream Bio’s research?
Upstream Bio focuses on developing treatments for inflammatory diseases, particularly severe respiratory disorders.
What is verekitug?
Verekitug is a monoclonal antibody targeting the receptor for TSLP, aimed at treating inflammatory response in various diseases.
Where can I learn more about Upstream Bio?
More information about Upstream Bio can be found on their official website at www.upstreambio.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$UPB Hedge Fund Activity
We have seen 2 institutional investors add shares of $UPB stock to their portfolio, and 2 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- STRS OHIO removed 1,800 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $33,858
- J.SAFRA ASSET MANAGEMENT CORP added 128 shares (+inf%) to their portfolio in Q3 2025, for an estimated $2,407
- N.E.W. ADVISORY SERVICES LLC added 60 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,128
- VERSANT CAPITAL MANAGEMENT, INC removed 10 shares (-1.8%) from their portfolio in Q3 2025, for an estimated $188
- NISA INVESTMENT ADVISORS, LLC added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
- AMALGAMATED BANK added 0 shares (+0.0%) to their portfolio in Q3 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$UPB Analyst Ratings
Wall Street analysts have issued reports on $UPB in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Truist Securities issued a "Buy" rating on 10/14/2025
To track analyst ratings and price targets for $UPB, check out Quiver Quantitative's $UPB forecast page.
Full Release
WALTHAM, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, today announced that Rand Sutherland, MD, Chief Executive Officer of Upstream Bio, will be participating in the following upcoming investor conferences in November:
-
2025 Truist Securities BioPharma Symposium, New York, NY
Thursday, November 6, 2025, Panel - 8:10 a.m. ET -
Stifel 2025 Healthcare Conference, New York, NY
Tuesday, November 11, 2025, Presentation - 9:20 a.m. ET
-
TD Cowen Immunology and Inflammation Summit, Virtual
Wednesday, November 12, 2025, Fireside Chat - 10:30 a.m. ET
Live webcasts of the Stifel and Cowen presentations will be available under the Events tab on the Investors section of Upstream Bio’s website on the day of the event. A replay of the webcasts will be posted on the Company's website following the presentations.
About Upstream Bio
Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Upstream Bio is developing verekitug, the only known antagonist currently in clinical development that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. Upstream Bio has advanced this highly potent monoclonal antibody into separate Phase 2 trials for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP), severe asthma and chronic obstructive pulmonary disease (COPD). Upstream Bio’s team is committed to maximizing verekitug’s unique attributes to address the substantial unmet needs for patients underserved by today’s standard of care. To learn more, please visit
www.upstreambio.com
.
Investor and Media Contact:
Meggan Buckwell
Director, Corporate Communications and Investor Relations
[email protected]
